Evidence suggests a deficit in NMDA receptor function is one underlying cause for schizophrenia. 1 We tested this hypothesis using the highly selective single photon emission tomography (SPET) NMDA receptor tracer, [ 123 I]CNS-1261. Significant reductions in relative NMDA receptor binding in left hippocampal medication-free, but not antipsychotic-treated, schizophrenic patients compared to healthy subjects were found.
[
123 I]CNS-1261 is an intrachannel NMDA receptor SPET probe that has been extensively developed with quantitative kinetic modeling methods in humans. 2 Direct challenge with ketamine has revealed a displacement greater than test-retest in all brain regions (max 20%). 3 We have recently reported the results of a study examining the impact of schizophrenia and antipsychotic treatment on [ 123 I]CNS-1261 binding. 4 Total volume of distribution (V T ) was the main outcome measure. V T is a measure that is linearly proportional to B max /K d , but does not control for f 1 and f 2 (free fractions of tracer in plasma and in tissue, respectively). We now extend the analysis using normalized-to-cortex binding indices to evaluate regional NMDA receptor binding incorporating the effects of nonspecific binding.
Healthy volunteers (n = 13), and three groups of schizophrenic patients: drug free (n = 5), typical antipsychotic treated (n = 7), and clozapine treated (n = 9) were recruited and underwent SPET scans using [
123 I]CNS-1261 as previously described. 4 Specific binding indices were calculated using the formulae BI 1 = V T -V R and BI 2 = (V T -V R )/V R , where V R was obtained from whole cortex. Statistical parametric analysis (SPM99) 5 was used to analyze BI 2 data in MNI space. Anatomical location of significant clusters was defined using Talairach Daemon. 6 ROIbased analyses using predefined user independent regions adapted from a template developed by Takeuchi et al. 7 were performed using in-house software to generate average BI 1 and BI 2 values for each region. Analysis of variance (ANOVA) was performed to compare mean BI 1 and BI 2 for all groups by region. Post hoc t-tests were performed in regions showing significant differences by group. Correlations were sought between BI values from ROI data and total PANSS scores, as well as positive, negative and general PANSS subscales. Correlations were also sought with age and duration of illness.
Comparison of BI 2 data using SPM99 revealed a single cluster of decreased binding in drug free schizophrenic patients compared with normal volunteers centered around a point corresponding to left uncus (hippocampus) (P = 0.034 corrected for multiple comparisons). ANOVA of the ROI-based data revealed that the hippocampus, superior frontal and posterior cerebral regions showed significant differences by group (P < 0.1 for both BI 1 and BI 2 ). NMDA receptor binding (BI 1 and BI 2 ) in the hippocampus relative to whole cortex was significantly lower in drug free patients compared to healthy volunteers (P < 0.001) and in drug-free patients compared to typical antipsychotic treated patients (P < 0.05). This decrease was entirely due to reduced BI 1 and BI 2 in left hippocampus (NV: P < 0.005, TA: P < 0.05) (Figure 1 ). Superior frontal BI 1 and BI 2 values were significantly lower in clozapine-treated patients than healthy volunteers (P < 0.05). The reduction was lateralized to the right side. BI 1 and BI 2 values in the posterior cerebral ROI (incorporating occipital lobe) were significantly higher in clozapine treated patients than healthy volunteers (P < 0.05). This increase was lateralized to the right side.
BI 1 and BI 2 in the hippocampal region were both significantly negatively correlated in patients on typical antipsychotics with total PANSS score (n = 7 BI 1 : r = 0.79, df = 5, P < 0.05; BI 2 : r = À0.78, df = 5, P < 0.05). They were most closely correlated with the negative PANSS subscale (n = 7 BI 1 : r = 0.93, df = 5, P < 0.01; BI 2 : r = À0.92, df = 5, P < 0.01). There were no significant correlations between BI 1 or BI 2 and any of the clinical rating scores in drug-free or clozapinetreated patients. BI 1 and BI 2 showed a significant positive correlation with illness duration in the middle inferior frontal cortex in drug-free patients (BI 1 : r = 0.970, df = 3, P < 0.01; BI 2 : r = 0.979, df = 3, P < 0.01). There was no significant correlation between BI and age in any region for any of the groups studied.
These data are in keeping with an NMDA dysfunction hypothesis of schizophrenia. Both typical and atypical antipsychotic drugs appear to modulate this system towards normality in vivo. These findings may open new avenues for pharmacotherapy, with drugs targeting the glutamatergic system.
